Virnich Daniel 4

What Happened

• Daniel Virnich, CEO of Oncology Institute, had an RSU award recorded (670,608 shares) and a related disposition: 98,534 shares were disposed (sold) at $3.07 per share for proceeds of $302,499. The filing indicates the sale was executed to cover tax liabilities arising from RSU vesting.

Key Details

• Transaction dates: reported for 2026-03-27; filing date 2026-04-01.
• Prices and values: 98,534 shares sold at $3.07 each = $302,499. RSU award recorded as 670,608 shares at $0.00 acquisition price (code A).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes:
  • F1: The RSU award follows a typical four-year vesting schedule (25% after one year, then three equal annual installments).
  • F2: The issuer executed the sale to cover the tax liabilities arising from the RSU vesting (i.e., sale-to-cover for taxes).
• Transaction codes: A = award/grant recorded; J = other acquisition/disposition (here used for the sale-to-cover). This appears to be a withholding/issuer-executed sale rather than an open-market discretionary sale by the insider.
• Timeliness: Filing shows transaction on Mar 27 and Form 4 filed Apr 1 (5 days later). The standard Section 16 reporting window is generally 2 business days; this gap may indicate a delayed filing—investors may want to verify timeliness.

Context

• The sale was a tax-withholding (sale-to-cover) related to RSU vesting, a routine administrative transaction that doesn’t necessarily signal a change in the CEO’s view of the company.
• The RSU award and its vesting schedule mean additional shares may vest over time, subject to continued service.